Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
IPO Year: 2021
Exchange: NASDAQ
Website: cogrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $1.00 → $1.50 | Neutral → Buy | B. Riley Securities |
| 7/30/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 11/3/2021 | $27.00 | Buy | B. Riley Securities |
| 11/3/2021 | $22.00 | Outperform | Oppenheimer |
– Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB – – Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L), 52% on activities of daily living, 91% on cognitive fluctuations, 62% on motor symptoms compared to placebo – PURCHASE, N.Y., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that James E. Galvin, MD, MPH will present topline results from the ‘SHIMMER' study of zervimesine (CT1812) in dementia with Lewy b
PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciardi will be participating at upcoming conferences taking place during the week of the JP Morgan Healthcare Conference 2025. "I am looking forward to these opportunities to discuss the incredible progress we have made in 2024 with our Alzheimer's and dementia with Lewy body (DLB) programs," stated Ms. Ricciardi. "We capped off 2024 with positive topline results from our Phase 2 SHIMMER study in patients with DLB and are looking forward to presenting
- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeutics and Dr. Galvin, a Principal Investigator, Will Host a Conference Call at 8am ET on December 18 to Review the Topline Data - PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER' study demonstrating CT1812 produced strong therapeutic responses ac
– Topline results in second dementia indication expected to be reported in December 2024 – PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the last patient has completed their final clinic visit in the Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB). The Company anticipates that topline results will be available in December 2024. "We would like to extend our appreciation to the patients and caregivers who participated in our study, without whom we would not have been able to accomplish this goal.
- Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer's Disease Biology - - Findings Support Disease-modifying Potential of CT1812 - PURCHASE, N.Y., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ:CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, provided an update on a biomarker1 analysis from the Phase 2 ‘SHINE' study in mild-to-moderate Alzheimer's disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau2172. Several blood-based measures of Alzheim
- CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 - PURCHASE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition") today reported financial results for the third quarter ended September 30, 2024, and provided a business update. "In the th
PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CEO Lisa Ricciardi will present live at the virtual Zacks SCR Life Sciences Investor Forum on November 14, 2024. The Company's presentation will focus primarily on the results from the successful Phase 2 ‘SHINE' study of CT1812 in mild-to-moderate Alzheimer's disease. In addition, Ms. Ricciardi will provide an overview of the Company's ongoing clinical programs, including the Phase 2 ‘SHIMMER' study of CT1812 in dementia with Lewy bodies. Topline results fr
- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented participant baseline characteristics in the Phase 2 ‘SHIMMER' study of mild-to-moderate dementia with Lewy bodies (DLB). The poster is being presented at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference being held October 29 – November 1, 2024 in Madrid, Spain and is available on Cognition's website. "Looking at the mean scores, participants who entered our DLB study had mild-to-modera
- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology - - ADAS-Cog 11 scores showed 95% slowing of decline - - MMSE scores showed 108% slowing of decline - - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 - - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented a pre-specified analysis of data fro
Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE' Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER' trial in DLB PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will deliver an oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference, which is taking place October 29 - November 1, 2024, in Madrid, Spain. "Dr. Woodward will
SC 13G/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)
SC 13G - COGNITION THERAPEUTICS INC (0001455365) (Subject)
SC 13D/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)
SC 13G/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)
SC 13D/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)
SC 13G - COGNITION THERAPEUTICS INC (0001455365) (Subject)
SC 13D/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)
SC 13D - COGNITION THERAPEUTICS INC (0001455365) (Subject)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
10-Q - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
10-Q - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously
Cantor Fitzgerald downgraded Cognition Therapeutics from Overweight to Neutral
B. Riley Securities initiated coverage of Cognition Therapeutics with a rating of Buy and set a new price target of $27.00
Oppenheimer initiated coverage of Cognition Therapeutics with a rating of Outperform and set a new price target of $22.00
PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements. "John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. We look forward to leveraging his skills, his relationships on Wall Street, and his strategic insights as we move forward together as a company," said Lisa Ricciard
PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®. "We are now enrolling participants in three clinical studies: two for mild-to-moderate Alzheimer's disease and one for dementia with Lewy bodies with plans to commence enrollment in studies for early Alzheimer's disease and dry age-related macular degeneration in the near-term,
PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the addition of Ellen B. Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition's board, having served as chief financial officer and treasurer for Fortune 500 companies, and as a board member for c
- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeutics and Dr. Galvin, a Principal Investigator, Will Host a Conference Call at 8am ET on December 18 to Review the Topline Data - PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER' study demonstrating CT1812 produced strong therapeutic responses ac
- CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 - PURCHASE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition") today reported financial results for the third quarter ended September 30, 2024, and provided a business update. "In the th
- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology - - ADAS-Cog 11 scores showed 95% slowing of decline - - MMSE scores showed 108% slowing of decline - - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 - - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented a pre-specified analysis of data fro
- Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB by YE 2024 - - Company to Host Investor Conference Call at 8:30 a.m. - PURCHASE, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the second quarter ended June 30, 2024, and provided a business update. "We announced favorable resul
PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference CallDate / TimeAugust 8, 2024 at 8:30am ET / 5:30am PTTelephone Access: US/Canada Participant Toll-Free Dial-in Number: (800) 715-9871U
PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference Call Information: Telephone Access: US/Canada Participant Toll-Free Dial-in Numb
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer's Disease Commenced Recruitment for 540-patient Phase 2 START Trial in Early Alzheimer's Disease Published Data from SNAP Study Affirming Target Engagement of Sigma-2 (σ-2) Receptor Patient Dosing Commenced in MAGNIFY Study for Geographic Atrophy PURCHASE, N.Y., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the "Company" or "Cognition"), today reported financial results for the second quarter ended June 30, 2023 an
PURCHASE, N.Y., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter on Tuesday, August 8, 2023 before the market opens. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review financial results and provide a business update. Conference Call Information: Telephone Access: US/New York Participant Dial-in Number: (646) 307-1963US/Canada Participant Toll-Free Dia
Results Show Positive Treatment Effect of CT1812 on Global and Regional Brain Activity Management Holding Webcast Conference Call at 8:00am ET Today NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative disorders by regulating cellular damage response pathways, today announced topline results from its Phase 2 double-blind, single-crossover SEQUEL study (NCT04735536) of CT1812 in 16 adults with mild-to-moderate Alzheimer's disease. The study, which was conducted in the Netherlands, met its primary endpoints for safety and tolerability and showed positive effects for
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative disorders by regulating cellular damage response pathways, announced that it will host a conference call and webcast on June 28, 2023, at 8:00am ET to discuss topline results from its Phase 2 SEQUEL Study (NCT04735536) for mild-to-moderate Alzheimer's disease. During the event, members of Cognition's leadership team and a principal investigator from the trial will review the results. The event will feature: Lisa Ricciardi, CEO, Cognition Therapeutics Anthony Caggiano, M.D., Ph.D., Chief Medical Officer and Head
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)